Trial
NCT02763384
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
The Leukemia and Lymphoma Society; National Institutes of Health (NIH); National Cancer Institute (NCI)
Condition
T-Acute Lymphoblastic Leukemia
Intervention
BL-8040
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-31